动脉血管活性

A. Bura-Rivière , H. Boccalon
{"title":"动脉血管活性","authors":"A. Bura-Rivière ,&nbsp;H. Boccalon","doi":"10.1016/j.emcaa.2005.09.012","DOIUrl":null,"url":null,"abstract":"<div><p>Peripheral artery disease is a highly prevalent manifestation of atherosclerosis that is associated with a substantial risk of illness and death and a marked reduction in ambulatory capacity and quality of life. Unfortunately, peripheral artery disease is under-treated with regard to risk factor modification, use of antiplatelet drugs, and treatment of symptoms. Patients with peripheral artery disease should be considered eligible for secondary prevention strategies, just as are patients with coronary artery disease. Aspirin or clopidogrel should be considered in all patients. Drugs that improve functional status, called vasoactive drugs, are also available. Their use should be limited to patients with intermittent claudication in whom, despite prolonged standard therapy and physical exercise, functional symptoms persist but with no need for revascularization. These treatments should be discontinued in the absence of clear amelioration of symptoms. Prostanoid agents have shown some benefits in patients with critical limb ischemia, in which no revascularisation is possible.</p></div>","PeriodicalId":100413,"journal":{"name":"EMC - Cardiologie-Angéiologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emcaa.2005.09.012","citationCount":"0","resultStr":"{\"title\":\"Vasoactifs artériels\",\"authors\":\"A. Bura-Rivière ,&nbsp;H. Boccalon\",\"doi\":\"10.1016/j.emcaa.2005.09.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Peripheral artery disease is a highly prevalent manifestation of atherosclerosis that is associated with a substantial risk of illness and death and a marked reduction in ambulatory capacity and quality of life. Unfortunately, peripheral artery disease is under-treated with regard to risk factor modification, use of antiplatelet drugs, and treatment of symptoms. Patients with peripheral artery disease should be considered eligible for secondary prevention strategies, just as are patients with coronary artery disease. Aspirin or clopidogrel should be considered in all patients. Drugs that improve functional status, called vasoactive drugs, are also available. Their use should be limited to patients with intermittent claudication in whom, despite prolonged standard therapy and physical exercise, functional symptoms persist but with no need for revascularization. These treatments should be discontinued in the absence of clear amelioration of symptoms. Prostanoid agents have shown some benefits in patients with critical limb ischemia, in which no revascularisation is possible.</p></div>\",\"PeriodicalId\":100413,\"journal\":{\"name\":\"EMC - Cardiologie-Angéiologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.emcaa.2005.09.012\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMC - Cardiologie-Angéiologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1762613705000394\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Cardiologie-Angéiologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762613705000394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

外周动脉疾病是动脉粥样硬化的一种高度流行的表现,与疾病和死亡的巨大风险以及行动能力和生活质量的显著降低有关。不幸的是,外周动脉疾病在风险因素的改变、抗血小板药物的使用和症状的治疗方面治疗不足。外周动脉疾病患者应被视为符合二级预防策略,冠状动脉疾病患者也是如此。所有患者均应考虑服用阿司匹林或氯吡格雷。改善功能状态的药物,称为血管活性药物,也可以买到。它们的使用应仅限于间歇性跛行患者,尽管他们进行了长期的标准治疗和体育锻炼,但功能症状仍然存在,但无需进行血运重建。在症状没有明显改善的情况下,应停止这些治疗。前列腺素类药物在严重肢体缺血患者中显示出一些益处,在这些患者中不可能进行血运重建。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Vasoactifs artériels

Peripheral artery disease is a highly prevalent manifestation of atherosclerosis that is associated with a substantial risk of illness and death and a marked reduction in ambulatory capacity and quality of life. Unfortunately, peripheral artery disease is under-treated with regard to risk factor modification, use of antiplatelet drugs, and treatment of symptoms. Patients with peripheral artery disease should be considered eligible for secondary prevention strategies, just as are patients with coronary artery disease. Aspirin or clopidogrel should be considered in all patients. Drugs that improve functional status, called vasoactive drugs, are also available. Their use should be limited to patients with intermittent claudication in whom, despite prolonged standard therapy and physical exercise, functional symptoms persist but with no need for revascularization. These treatments should be discontinued in the absence of clear amelioration of symptoms. Prostanoid agents have shown some benefits in patients with critical limb ischemia, in which no revascularisation is possible.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信